Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.67 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.67 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.40 |
| ▸ | FNTB | P49356 | 2/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20787756 | 1.00 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL6665444 | 0.92 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL3797018 | 0.91 | PTGS1 (0.63) | PTGS1GSTK1GLO1NOD1GLP1R | |
| SCHEMBL20787748 | 0.91 | PTGS1 (0.63) | PTGS1GSTK1GLO1NOD1GLP1R | |
| SCHEMBL28383431 | 0.90 | NOD1 (0.65) | PTGS1GSTK1NOD1GLP1R | |
| SCHEMBL3800861 | 0.90 | NOD1 (0.65) | PTGS1GSTK1NOD1GLP1R | |
| SCHEMBL20787762 | 0.90 | NOD1 (0.65) | PTGS1GSTK1NOD1GLP1R | |
| SCHEMBL574321 | 0.90 | NOD1 (0.65) | PTGS1GSTK1NOD1GLP1R | |
| SCHEMBL3796046 | 0.90 | NOD1 (0.65) | PTGS1GSTK1NOD1GLP1R | |
| SCHEMBL9986539 | 0.90 | NOD1 (0.65) | PTGS1GSTK1NOD1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025134153-A1 | A COSMETIC COMPOSITION COMPRISING THIOPYRIDINONE COMPOUNDS AND REDUCING AGENT | L'ORÉAL (FR) | 2025-06-26 | — | — | WO | claimed |
| EP-4370144-A1 | GLUTAHTIONE C4 AGAINST AIRWAY AFFECTIONS | Redox-co S.r.l. (IT) | 2024-05-22 | — | — | EP | claimed |
| CN-117693352-A | Glutathione C4 against airway diseases | 瑞道克斯-科有限公司 | 2024-03-12 | — | — | CN | claimed |
| EP-3270889-B1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2024-02-07 | — | — | EP | claimed |
| WO-2023285984-A1 | GLUTAHTIONE C4 AGAINST AIRWAY AFFECTIONS | REDOX-CO S.R.L. (IT) | 2023-01-19 | — | — | WO | claimed |
| WO-2022074181-A1 | NANOCARRIER FORMULATIONS FOR INHALATION | EnhanX Biopharm Inc. (TW) | 2022-04-14 | — | — | WO | claimed |
| EP-3395372-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | ENHANX BIOPHARM INC (TW) | 2022-04-06 | — | — | EP | claimed |
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | MIRECA MEDICINES GMBH (DE) | 2019-06-18 | — | — | US | claimed |
| EP-2398500-B1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2 BBB MEDICINES B V (NL) | 2019-03-13 | — | — | EP | claimed |
| EP-3395372-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | 2-BBB Medicines B.V. (NL) | 2018-10-31 | — | — | EP | claimed |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2018-03-29 | — | — | US | claimed |
| EP-3270889-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | Mireca Medicines GmbH (DE) | 2018-01-24 | — | — | EP | claimed |
| WO-2016146669-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2016-09-22 | — | — | WO | claimed |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2014-08-14 | — | — | US | claimed |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2011-12-15 | — | — | US | claimed |
| WO-2025169070-A1 | COMPOUND FOR THE TREATMENT OF DISORDERS OR PATHOLOGIES OF THE OCULAR SURFACE | REDOX-CO S.R.L. (IT) | 2025-08-14 | — | — | WO | disclosed |
| WO-2025134153-A1 | A COSMETIC COMPOSITION COMPRISING THIOPYRIDINONE COMPOUNDS AND REDUCING AGENT | L'ORÉAL (FR) | 2025-06-26 | — | — | WO | disclosed |
| EP-1701973-A1 | GLUTATHIONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VIRAL DISEASES | Benatti, Umberto (IT) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063795-A1 | GLUTATHIONE DERIVATIVES AND THEIR USES FOR THE TREATMENT OF VIRAL DISEASES | BENATTI UMBERTO (IT) | 2005-07-14 | — | — | WO | disclosed |
| EP-0536231-A1 | A PROCESS FOR THE PREPARATION OF GLUTATHIONE S-ACYL DERIVATIVES, COMPOUNDS OBTAINED FROM SAID PROCESS AND AN INTERMEDIATE USEFUL FOR THE PREPARATION THEREOF. | BOEHRINGER MANNHEIM ITALIA (IT) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10322087-B2 | Targeted liposomal delivery of cGMP analogues | PDE6C, PDE2A, GMPS | PTGS1 131/4885GSTK1 64/4885GLO1 155/4885 |
| US-20110305751-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | PTGS1 292/4885GSTK1 13/4885GLO1 93/4885 |
| US-20180085311-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | PDE6C, PDE2A, GMPS | PTGS1 131/4885GSTK1 71/4885GLO1 166/4885 |
| US-20140227185-A1 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | GSS, GSTO1, SLC7A11 | PTGS1 292/4885GSTK1 13/4885GLO1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.